The dose-response relationship in Phase I clinical trials and beyonduse, meaning, and assessment

Pharmacology and Therapeutics

Volumn 88, Issue 1, 2000, Pages 33-58

  Emilien, Gérard ^a,d   Van Meurs, Willem ^b,c   Maloteaux, Jean Marie ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d NONE   (France)

Author keywords

Clinical trial; Dose response; Pharmacodynamic; Pharmacokinetic; Phase I; Quantal; Quantitative

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; FUROSEMIDE; NIFEDIPINE; THEOPHYLLINE;

CLINICAL PHARMACOLOGY; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG DOSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; HUMAN; MATHEMATICAL MODEL; METHODOLOGY; MODEL; PATHOLOGY; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SLOW RELEASE FORMULATION; TOXICOLOGY;

ANIMALS; CLINICAL TRIALS, PHASE I; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; RESEARCH DESIGN;

EID: 0033801056     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(00)00077-2     Document Type: Review

References (105)

1. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam
2. Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect
3. A molecular basis for drug action
4. A test of homogeneity of means under restricted alternatives
5. Estimating population kinetics
6. Kinetics and dynamics of furosemide and slow-acting furosemide
7. Therapeutic monitoring of theophylline rationale and current status
8. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neurtropenia
9. Concentration-effect relationship of the positive chronotropic and hypokalaemic effects of fenoterol in healthy women of childbearing age
10. Resistance to loop diuretics; why it happens and what to do about it
11. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The 'wooden shoe' paradigm
12. Psychomotor performance; investigating the dose-response relationship for caffeine and theophylline in elderly volunteers
13. Caffeine and human cerebral blood flow; a positron emission tomography study
14. Differences in nifedipine concentration-effect relationship between capsule and slow release tablet administration
15. A study of distribution-free tests for umbrella alternatives
16. On the comparison of umbrella pattern treatment means with a control mean
17. A review of tests for detecting a monotone dose-response relationship with ordinal response data
18. Crossover trials are only useful when there is a positive correlation between the response to different treatment modalities
19. 2-adrenergic receptor antagonist ethoxyidazoxan in healthy volunteers
20. Two-stage linear models
21. Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer
22. Comparison of four basic models of indirect pharmacodynamic responses
23. Effects of acute and chronic caffeine use on the cerebrovascular, cardiovascular and hormonal response to orthostasis in healthy volunteers
24. 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans
25. A multiple comparison procedure for comparing several treatments with a control
26. New table for multiple comparisons with a control
27. Flexible regression models with cubic splines
28. Pharmacodynamic and pharmacokinetic study of a slow release formulation in man
29. Pharmacokinetics and pharmacodynamics of alprazolam following single and multiple oral doses of a sustained-release formulation
30. Interchangeability and predictive performance of empirical tolerance models
31. Comparison of two benzodiazepines with differing accumulation; behavioral changes during and after three weeks of dosing
32. Clockwise hysteresis or proteresis
33. Drug absorption rate; a critical component of bioequivalence assessment in psychopharmacology
34. Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modelin
35. Acute dose-effect relationships of caffeine and mental performance, ECG, cardiovascular and subjective parameters
36. Optimal designs for comparing test treatments with controls
37. A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products
38. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function
39. Pharmacokinetic-pharmacodynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration
40. Understanding the dose-effect relationship; clinical application of pharmacokinetic-pharmacodynamic models
41. Kinetics of pharmacologic response
42. The rapid development of physical dependence on barbiturates
43. Physiologic indirect response models characterize adverse types of pharmacodynamic effects
44. Convergence of direct and indirect pharmacodynamic response models
45. The time course of delivery of furosemide into urine; an independent determinant of overall response
46. The study of drug-receptor interaction in in vivo systems
47. Nifedipine kinetics and dynamics in healthy volunteers
48. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans
49. Pharmacokinetic-pharmacodynamic modelling as applied to bronchial asthma
50. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer
51. Predicting effective drug concentrations for individual patients
52. Pharmacokinetic analysis of the effect of barbiturate on the anticoagulant action of warfarin in man
53. Concentration- or effect-controlled clinical trials with sparse data
54. The effects of low doses of caffeine on human performance and mood
55. The acute effects of corticosteroids on cognition; integration of animal and human model studies
56. K-sample rank tests for umbrella alternatives
57. Tests for trend and dose response; misinterpretations and alternatives
58. Population pharmacodynamic model for ketorolac analgesia
59. Pharmacodynamic modelling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing; characterization of tolerance
60. Acute and subacute effects of diazepam on human performance; comparison of plain tablet and controlled release capsule
61. Mechanism-based PK/PD model for the lymphocyteopenia induced by endogenous and exogenous corticosteroids
62. Is there a concentration-effect relationship for sulphonylureas?
63. Kinetics of pharmacologic effects in man; the anticoagulant action of warfarin
64. Pharmacokinetic-pharmacodynamic relationship of apomorphine in patients with Parkinson's disease
65. Single and multiple dose kinetics of clobazam, and clinical effects during multiple dosage
66. Kinetics of the anticoagulant effect of bishydroxycoumarin in man
67. The concentration-effect relationship of quinine-induced hearing impairment
68. Pharmacodynamic model of tolerance; application to nicotine
69. Nefazone and imipramine in major depression; a placebo-controlled trial
70. Clinical development
71. Pharmacokinetic and pharmacodynamic profile of donepezil HCL following oral doses
72. Loop diuretics for chronic renal insufficiency; a continuous infusion is more efficacious than bolus therapy
73. Tiagabine therapy for complex partial seizures. A dose-frequency study
74. Assessment of pharmacodynamics of a new 'controlled-release' form of diazepam (Valium® CR Roche) by quantitative EEG and psychomotor analysis in neurotic subjects
75. Population dose versus response of betaxolol and atenolol; a comparison of potency and variability
76. The randomized concentration-controlled trial; an evaluation of its sample size efficiency
77. Characterization of four basic models of indirect pharmacodynamic responses
78. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena
79. Simultaneous modelling of pharmacokinetics and pharmacodynamics; application to d-tubocurarine
80. Pharmacokinetic-pharmacodynamic modelling of caffeine; tolerance to pressor effects
81. A non-parametric equivalent of William's test for contrasting increasing dose levels of a treatment
82. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects
83. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration
84. Optimization in clinical trials and combination drug development
85. What is the benefit of increasing the sulphonylurea dosage?
86. Design and analysis of phase I clinical trials
87. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics
88. Fourth-generation model for corticosteroid pharmacodynamics; a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver
89. Mechanism-based pharmacokinetic-pharmacodynamic modelling of benzodiazepines
90. Clinical pharmacokinetics and diuretic effect of furosemide in plain tablet and retard capsule with normal subjects and cirrhotic patients
91. Simultaneous modelling of pharmacokinetics and pharmacodynamics with non-parametric kinetic and dynamic models
92. Analysis of drug-receptor interactions in vivo; a new approach in pharmacokinetic-pharmacodynamic modelling
93. Pharmacokinetic/pharmacodynamic models and methods
94. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses
95. Impaired effect of sulphonylurea following increased dosage
96. Pharmacodynamic modelling of furosemide tolerance after multiple intravenous administration
97. Sleep endocrine effects of megestrol acetate in healthy men
98. A test for differences between treatment means when several dose levels are compared with a zero dose control
99. The comparison of several dose levels with a zero dose control
100. Dose-response estimands. Comment on compliance as an explanatory variable in clinical trials